Formation of bradykinin: A major contributor to the innate inflammatory response

Advances in Immunology

Volumn 86, Issue , 2005, Pages 159-208

  Joseph, Kusumam ^a   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; CELL SURFACE PROTEIN; CYTOKERATIN 1; HEAT SHOCK PROTEIN 90; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; KININ; KININOGEN; PLASMA PROTEIN; PREKALLIKREIN; UROKINASE RECEPTOR;

AFFINITY CHROMATOGRAPHY; ALLERGIC DISEASE; BINDING AFFINITY; BINDING SITE; BLOOD PRESSURE REGULATION; CELL SURFACE; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; ENZYME KINETICS; ENZYME SUBSTRATE; FIBRINOLYSIS; HEAVY CHAIN; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIGHT CHAIN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; REVIEW; STOICHIOMETRY; UMBILICAL VEIN; VASCULAR DISEASE;

EID: 13444267658     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(04)86005-X     Document Type: Article

References (246)

1. Alving B.M., Hojima Y., Pisano J.J., Mason B.L., Buckingham R.E. Jr., Mozen M.M., Finlayson J.S. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N. Engl. J. Med. 299:1978;66-70
2. Alving B.M., Tankersley D.L., Mason B.L., Rossi F., Aronson D.L., Finlayson J.S. Contact-activated factors: Contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J. Lab. Clin. Med. 96:1980;334-346
3. Atkins P.C., Miragliotta G., Talbot S.F., Zweiman B., Kaplan A.P. Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin. J. Immunol. 139:1987;2744-2748
4. Atkins P.C., Kaplan A.P., von Allmen C., Moskovitz A., Zweiman B. Activation of the coagulation pathway during ongoing allergic cutaneous reactions in humans. J. Allergy Clin. Immunol. 89:1992;552-559
5. Baglia F.A., Walsh P.N. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J. Biol. Chem. 275:2000;20514-20519
6. Baglia F.A., Badellino K.O., Li C.Q., Lopez J.A., Walsh P.N. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J. Biol. Chem. 277:2002;1662-1668
7. Baird T.R., Walsh P.N. Activated platelets but not endothelial cells participate in the initiation of the consolidation phase of blood coagulation. J. Biol. Chem. 277:2002;28498-28503
8. Baird T.R., Walsh P.N. Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells. J. Biol. Chem. 278:2003;20618-20623
9. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270:1995;14477-14484
10. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem. 271:1996;16603-16608
11. 2- macroglobulin with proteinases: Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem. J. 133:1973;709-724
12. Baumgarten C.R., Togias A.G., Naclerio R.M., Lichtenstein L.M., Norman P.S., Proud D. Influx of kininogens into nasal secretions after antigen challenge of allergic individuals. J. Clin. Invest. 76:1985;191-197
13. Baumgarten C.R., Nichols R.C., Naclerio R.M., Lichtenstein L.M., Norman P.S., Proud D. Plasma kallikrein during experimentally induced allergic rhinitis: Role in kinin formation and contribution to TAME-esterase activity in nasal secretions. J. Immunol. 137:1986a;977-982
14. Baumgarten C.R., Nichols R.C., Naclerio R.M., Proud D. Concentrations of glandular kallikrein in human nasal secretions increase during experimentally induced allergic rhinitis. J. Immunol. 137:1986b;1323-1328
15. Beeler D.L., Marcum J.A., Schiffman S., Rosenberg R.D. Interaction of factor XIa and antithrombin in the presence and absence of heparin. Blood. 67:1986;1488-1492
16. Beierwaltes W.H., Carretero O.A., Scicli A.G., Vavrek R.J., Stewart J.M. Competitive analog antagonists of bradykinin in the canine hindlimb. Proc. Soc. Exp. Biol. Med. 186:1987;79-83
17. Bouma B.N., Meijers J.C. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr. Opin. Hematol. 7:2000;266-272
18. Bradford H.N., Dela Cadena R.A., Kunapuli S.P., Dong J.F., Lopez J.A., Colman R.W. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood. 90:1997;1508-1515
19. Brown C.F., Osmond D.H. Factor XII and prekallikrein-kallikrein-kinin in the cryoactivation of human plasma prorenin. Clin. Sci. 66:1984;533-539
20. Brunnee T., La Porta C., Reddigari S.R., Salerno V.M., Kaplan A.P., Silverberg M. Activation of factor XI in plasma is dependent on factor XII [see comment]. Blood. 81:1993;580-586
21. Brunnee T., Reddigari S.R., Shibayama Y., Kaplan A.P., Silverberg M. Mast cell derived heparin activates the contact system: A link to kinin generation in allergic reactions. Clin. Exp. Allergy. 27:1997;653-663
22. Bush A.I., Pettingell W.H., Multhaup G., d Paradis M., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer A β amyloid formation by zinc [see comment]. Science. 265:1994;1464-1467
23. Caldwell P.R., Seegal B.C., Hsu K.C., Das M., Soffer R.L. Angiotensin-converting enzyme: Vascular endothelial localization. Science. 191:1976;1050-1051
24. Cameron C.L., Fisslthaler B., Sherman A., Reddigari S., Silverberg M. Studies on contact activation: Effects of surface and inhibitors. Med. Prog. Technol. 15:1989;53-62
25. Carpenter C.B., Ruddy S., Shehadeh I.H., Muller-Eberhard H.J., Merrill J.P., Austen K.F. Complement metabolism in man: Hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary, angioedema (HAE). J. Clin. Invest. 48:1969;1495-1505
26. Cochrane C.G., Revak S.D. Dissemination of contact activation in plasma by plasma kallikrein. J. Exp. Med. 152:1980;608-619
27. Cochrane C.G., Revak S.D., Wuepper K.D. Activation of Hageman factor in solid and fluid phases: A critical role of kallikrein. J. Exp. Med. 138:1973;1564-1583
28. Colman R.W. Activation of plasminogen by human plasma kallikrein. Biochem. Biophys. Res. Commun. 35:1969;273-279
29. Colman R.W., Schmaier A.H. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 90:1997;3819-3843
30. Colman R.W., Bagdasarian A., Talamo R.C., Scott C.F., Seavey M., Guimaraes J.A., Pierce J.V., Kaplan A.P. Williams trait: Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J. Clin. Invest. 56:1975;1650-1662
31. Colman R.W., Wachtfogel Y.T., Kucich U., Weinbaum G., Hahn S., Pixley R.A., Scott C.F., de Agostini A., Burger D., Schapira M. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood. 65:1985;311-318
32. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J., Mazar A., McCrae K.R. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 100:1997;1481-1487
33. Creticos P.S., Peters S.P., Adkinson N.F. Jr., Naclerio R.M., Hayes E.C., Norman P.S., Lichtenstein L.M. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N. Engl. J. Med. 310:1984;1626-1630
34. Crutchley D.J., Ryan J.W., Ryan U.S., Fisher G.H. Bradykinin-induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells: Studies with lower homologs and calcium antagonists. Biochim. Biophys. Acta. 751:1983;99-107
35. Cugno M., Hack C.E., de Boer J.P., Eerenberg A.J., Agostoni A., Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med. 121:1993;38-43
36. Cugno M., Cicardi M., Coppola R., Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology. 33:1996;361-364
37. Curd J.G., Prograis L.J. Jr., Cochrane C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. 152:1980;742-747
38. de Agostini A., Lijnen H.R., Pixley R.A., Colman R.W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J. Clin. Invest. 73:1984;1542-1549
39. Dedio J., Muller-Esterl W. Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells. FEBS Lett. 399:1996;255-258
40. Dedio J., Jahnen-Dechent W., Bachmann M., Muller-Esterl W. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. J. Immunol. 160:1998;3534-3542
41. Derkx F.H., Bouma B.N., Schalekamp M.P., Schalekamp M.A. An intrinsic factor XII-prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature. 280:1979;315-316
42. DiScipio R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology. 45:1982;587-595
43. Donaldson V.H. Mechanisms of activation of C′1 esterase in hereditary angioneurotic edema plasma in vitro. J. Exp. Med. 127:1968;411-429
44. Donaldson V.H., Glueck H.I., Fleming T. Brief recordings: Rheumatoid arthritis in a patient with Hageman trait. N. Engl. J. Med. 286:1972;528-530
45. Donaldson V.H., Glueck H.I., Miller M.A., Movat H.Z., Habal F. Kininogen deficiency in Fitzgerald trait: Role of high molecular weight kininogen in clotting and fibrinolysis. J. Lab. Clin. Med. 87:1976;327-337
46. Donaldson V.H., Rosen F.S., Bing D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans. Assoc. Am. Physicians. 90:1977;174-183
47. Dunn J.T., Kaplan A.P. Formation and structure of human Hageman factor fragments. J. Clin. Invest. 70:1982;627-631
48. Dunn J.T., Silverberg M., Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J. Biol. Chem. 257:1982;1779-1784
49. Erdos E.G., Sloane G.M. An enzyme in human plasma that inactivates bradykinin and kallidins. Biochem. Pharmacol. 11:1962;585
50. Fernando L.P., Fernando A.N., Joseph K., Kaplan A.P. Assessment of the role of heparan sulfate in high molecular weight kininogen binding to human umbilical vein endothelial cells. J. Thromb. Haemost. 1:2003a;2444-2449
51. Fernando L.P., Natesan S., Joseph K., Kaplan A.P. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thromb. Haemost. 90:2003b;787-795
52. Fields T., Ghebrehiwet B., Kaplan A.P. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J. Allergy Clin. Immunol. 72:1983;54-60
53. Forbes C.D., Pensky J., Ratnoff O.D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J. Lab. Clin. Med. 76:1970;809-815
54. Frank M.M., Sergent J.S., Kane M.A., Alling D.W. ε-Aminocaproic acid therapy of hereditary angioneurotic edema: A double-blind study. N. Engl. J. Med. 286:1972;808-812
55. Gailani D., Broze G.J. Jr. Factor XI activation in a revised model of blood coagulation. Science. 253:1991;909-912
56. 2-macroglobulin. J. Immunol. 113:1974;1928-1934
57. Ghebrehiwet B., Silverberg M., Kaplan A.P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 153:1981;665-676
58. Ghebrehiwet B., Randazzo B.P., Dunn J.T., Silverberg M., Kaplan A.P. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J. Clin. Invest. 71:1983;1450-1456
59. Ghebrehiwet B., Lim B.L., Peerschke E.I., Willis A.C., Reid K.B. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J. Exp. Med. 179:1994;1809-1821
60. Gigli I., Mason J.W., Colman R.W., Austen K.F. Interaction of plasma kallikrein with the C1 inhibitor. J. Immunol. 104:1970;574-581
61. Ginsberg M.H., Jaques B., Cochrane C.G., Griffin J.H. Urate crystal-dependent cleavage of Hageman factor in human plasma and synovial fluid. J. Lab. Clin. Med. 95:1980;497-506
62. Gjonnaess H. Cold promoted activation of factor VII. 3. Relation to the kallikrein system. Thromb. Diathesis Haemorrhagica. 28:1972;182-193
63. Goldsmith G., Saito H., Ratnoff O.D. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J. Clin. Invest. 12:1978;54
64. Gordon E.M., Ratnoff O.D., Saito H., Donaldson V.H., Pensky J., Jones P.K. Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. J. Lab. Clin. Med. 96:1980;762-769
65. Gordon E.M., Douglas J., Ratnoff O.D. Influence of augmented Hageman factor (factor XII) titers on the cryoactivation of plasma prorenin in women using oral contraceptive agents. J. Clin. Invest. 72:1983;1833-1838
66. Gounaris A.D., Brown M.A., Barrett A.J. Human plasma α-cysteine proteinase inhibitor: Purification by affinity chromatography, characterization and isolation of an active fragment. Biochem. J. 221:1984;445-452
67. Greengard J.S., Griffin J.H. Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry. 23:1984;6863-6869
68. Griffin J.H. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc. Natl. Acad. Sci. USA. 75:1978;1998-2002
69. Griffin J.H., Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc. Natl. Acad. Sci. USA. 73:1976;2554-2558
70. Gustafson E.J., Schutsky D., Knight L.C., Schmaier A.H. High molecular weight kininogen binds to unstimulated platelets. J. Clin. Invest. 78:1986;310-318
71. Harpel P.C. Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure. J. Exp. Med. 138:1973;508-521
72. 2-macroglobulin-kallikrein complexes. J. Biol. Chem. 260:1985;4257-4263
73. Hasan A.A., Zhang J., Samuel M., Schmaier A.H. Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells. Thromb. Haemost. 74:1995;1088-1095
74. Hasan A.A., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc. Natl. Acad. Sci. USA. 95:1998;3615-3620
75. Hauert J., Nicoloso G., Schleuning W.D., Bachmann F., Schapira M. Plasminogen activators in dextran sulfate-activated euglobulin fractions: A molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood. 73:1989;994-999
76. 1-antitrypsin. J. Exp. Med. 140:1974;1615-1630
77. Herwald H., Hasan A.A., Godovac-Zimmermann J., Schmaier A.H., Muller-Esterl W. Identification of an endothelial cell binding site on kininogen domain D3. J. Biol. Chem. 270:1995;14634-14642
78. Herwald H., Dedio J., Kellner R., Loos M., Muller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells: Identity with the gC1q receptor. J. Biol. Chem. 271:1996;13040-13047
79. Higashiyama S., Ohkubo I., Ishiguro H., Kunimatsu M., Sawaki K., Sasaki M. Human high molecular weight kininogen as a thiol proteinase inhibitor: Presence of the entire inhibition capacity in the native form of heavy chain. Biochemistry. 25:1986;1669-1675
80. Hirsch E.F., Nakajima T., Oshima G., Erdos E.G., Herman C.M. Kinin system responses in sepsis after trauma in man. J. Surg. Res. 17:1974;147-153
81. Hojima Y., Cochrane C.G., Wiggins R.C., Austen K.F., Stevens R.L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 63:1984;1453-1459
82. Hong S.L. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb. Res. 18:1980;787-795
83. Hsu T.C., Shore S.K., Seshsmma T., Bagasra O., Walsh P.N. Molecular cloning of platelet factor XI, an alternative splicing product of the plasma factor XI gene. J. Biol. Chem. 273:1998;13787-13793
84. Huisveld I.A., Hospers J.E.H., van Heeswijk G.M., Bernink M.J.E., Erich W.B.M., Bouma B.N. Contribution of contact activation factors to urokinase-related fibrinolytic activityin whole human plasma. Thromb. Haemost. 54:1985;102. [abstract]
85. Iatridis P.G., Ferguson J.H. Active Hageman factor: A plasma lysokinase of the human fibrinolytic system. J. Clin. Invest. 41:1962;1277
86. Ichinose A., Fujikawa K., Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 261:1986;3486-3489
87. Ishiguro H., Higashiyama S., Ohkubo I., Sasaki M. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies. Biochemistry. 26:1987;7021-7029
88. Jacobsen S. Separation of two separate substrates for plasma kinin forming enzymes. Nature. 210:1966;98-99
89. Jaffa A.A., Durazo-Arvizu R., Zheng D., Lackland D.T., Srikanth S., Garvey W.T., Schmaier A.H., Group D.E.S. Plasma prekallikrein: A risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes. 52:2003;1215-1221
90. Jespersen J., Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen: Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb. Haemost. 54:1985;454-459
91. Jiang Y., Nawarawong W., Meloni F.J., Schmaier A.H. Insights on monoclonal antibodies to kininogens' heavy chain which influence kininogens' binding to platelets. Thromb. Haemost. 68:1992a;143-148
92. Jiang Y.P., Muller-Esterl W., Schmaier A.H. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J. Biol. Chem. 267:1992b;3712-3717
93. Jong Y.J., Dalemar L.R., Seehra K., Baenziger N.L. Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease. Int. Immunopharmacol. 2:2002;1833-1840
94. Jorg M., Binder B.R. Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb. Res. 39:1985;323-331
95. Joseph K., Ghebrehiwet B., Peerschke E.I., Reid K.B., Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proc. Natl. Acad. Sci. USA. 93:1996;8552-8557
96. Joseph K., Nakazawa Y., Bahou W.F., Ghebrehiwet B., Kaplan A.P. Platelet glycoprotein Ib: A zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Mol. Med. 5:1999a;555-563
97. Joseph K., Shibayama Y., Nakazawa Y., Peerschke E.I., Ghebrehiwet B., Kaplan A.P. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Aβ protein of Alzheimer's disease. Immunopharmacology. 43:1999b;203-210
98. Joseph K., Ghebrehiwet B., Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin. Immunol. 92:1999c;246-255
99. Joseph K., Ghebrehiwet B., Kaplan A.P. Activation of the kinin-forming cascade on the surface of endothelial cells. Biol. Chem. 382:2001a;71-75
100. Joseph K., Shibayama Y., Ghebrehiwet B., Kaplan A.P. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb. Haemost. 85:2001b;119-124
101. Joseph K., Tholanikunnel B.G., Kaplan A.P. Activation of the bradykinin-forming cascade on endothelial cells: A role for heat shock protein 90. Int. Immunopharmacol. 2:2002a;1851-1859
102. Joseph K., Tholanikunnel B.G., Kaplan A.P. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc. Natl. Acad. Sci. USA. 99:2002b;896-900
103. Juhlin L., Michaelsson G. Vascular reactions in hereditary angioneurotic edema. Acta Derm. Venereol. 49:1969;20-25
104. Kaplan A.P., Austen K.F. A pre-albumin activator of prekallikrein. J. Immunol. 105:1970;802-811
105. Kaplan A.P., Austen K.F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J. Exp. Med. 133:1971;696-712
106. Kaplan A.P., Silverberg M. The coagulation-kinin pathway of human plasma. Blood. 70:1987;1-15
107. Kaplan A.P., Kay A.B., Austen K.F. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med. 135:1972;81-97
108. Kaplan A.P., Joseph K., Shibayama Y., Reddigari S., Ghebrehiwet B., Silverberg M. The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation. Adv. Immunol. 66:1997;225-272
109. Kaplan A.P., Joseph K., Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109:2002;195-209
110. Kellermann J., Lottspeich F., Henschen A., Muller-Esterl W. Amino acid sequence of the light chain of human high molecular mass kininogen. Adv. Exp. Med. Biol. 198:1986a;85-89
111. Kellermann J., Lottspeich F., Henschen A., Muller-Esterl W. Completion of the primary structure of human high-molecular-mass kininogen: The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. Eur. J. Biochem. 154:1986b;471-478
112. Kellermeyer R.W., Breckenridge R.T. The inflammatory process in acute gouty arthritis. 1. Activation of Hageman factor by urate crystals. J. Lab. Clin. Med. 63:1965;307
113. Kitamura N., Kitagawa H., Fukushima D., Takagaki Y., Miyata T., Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. J. Biol. Chem. 260:1985;8610-8617
114. Klemperer M.R., Donaldson V.H., Rosen F.S. Effect of C′1 esterase on vascular permeability in man: Studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J. Clin. Invest. 47:1968;604-611
115. Kluft C. Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis. 5:1976;136-146
116. Kluft C. Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: Involvement of C1-inactivator. Haemostasis. 6:1977;351-369
117. Kluft C., Wijngaards G., Jie A.F. Intrinsic plasma fibrinolysis: Involvement of urokinase-related activity in the factor XII-independent plasminogen proactivator pathway. J. Lab. Clin. Med. 103:1984;408-419
118. Laake K., Vennerod A.M., Haugen G., Gjonnaess H. Cold-promoted activation of factor VII in human plasma: Studies on the associated acyl-arginine esterase activity. Thromb. Res. 4:1974;769-785
119. Lenich C., Pannell R., Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb. Haemost. 74:1995;698-703
120. Lin Y., Harris R.B., Yan W., McCrae K.R., Zhang H., Colman R.W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood. 90:1997;690-697
121. Lipscomb M.S., Walsh P.N. Human platelets and factor XI. Localization in platelet membranes of factor XI-like activity and its functional distinction from plasma factor XI. J. Clin. Invest. 63:1979;1006-1014
122. Londino A.V. Jr., Luparello F.J. Factor XII deficiency in a man with gout and angioimmunoblastic lymphadenopathy. Arch. Internal Med. 144:1984;1497-1498
123. Lottspeich F., Kellermann J., Henschen A., Rauth G., Muller-Esterl W. Human low-molecular-mass kininogen: Amino-acid sequence of the light chain; homology with other protein sequences. Eur. J. Biochem. 142:1984;227-232
124. Loza J.P., Gurewich V., Johnstone M., Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: A mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb. Haemost. 71:1994;347-352
125. Lu G., Meier K.E., Jaffa A.A., Rosenzweig S.A., Egan B.M. Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells. Hypertension. 31:1998;978-985
126. Lundh B., Laurell A.B., Wetterqvist H., White T., Granerus G. A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid: Studies on C′1 esterase inhibitor, C′1 activation, plasminogen level and histamine metabolism. Clin. Exp. Immunol. 3:1968;733-745
127. Mahdi F., Shariat-Madar Z., Todd R.F. III, Figueroa C.D., Schmaier A.H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood. 97:2001;2342-2350
128. Mahdi F., Madar Z.S., Figueroa C.D., Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood. 99:2002;3585-3596
129. Mahdi F., Shariat-Madar Z., Schmaier A.H. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. J. Biol. Chem. 278:2003;43983-43990
130. Mandle R.J., Colman R.W., Kaplan A.P. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc. Natl. Acad. Sci. USA. 73:1976;4179-4183
131. Mandle R.J. Jr., Kaplan A.P. Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood. 54:1979;850-862
132. Marceau F., Bachvarov D.R. Kinin receptors. Clin. Rev. Allergy Immunol. 16:1998;385-401
133. Mason J.W., Kleeberg U., Dolan P., Colman R.W. Plasma kallikrein and Hageman factor in gram-negative bacteremia. Ann. Internal Med. 73:1970;545-551
134. McConnell D.J. Inhibitors of kallikrein in human plasma. J. Clin. Invest. 51:1972;1611-1623
135. McDonagh R.P. Jr., Ferguson J.H. Studies on the participation of Hageman factor in fibrinolysis. Thromb. Diathesis Haemorrhagica. 24:1970;1-9
136. Meier H.L., Pierce J.V., Colman R.W., Kaplan A.P. Activation and function of human Hageman factor: The role of high molecular weight kininogen and prekallikrein. J. Clin. Invest. 60:1977;18-31
137. Miles L.A., Rothschild Z., Griffin J.H. Dextran sulphate stimulated fibrinolytic activity in whole human plasma: Dependence on the contact activation system and on a urokinase-related antigen [abstract]. Thromb. Haemost. 46:1981;211
138. Miles L.A., Greengard J.S., Griffin J.H. A comparison of the abilities of plasma kallikrein, β-factor XIIa, factor XIa and urokinase to activate plasminogen. Thromb. Res. 29:1983a;407-417
139. Miles L.A., Rothschild Z., Griffin J.H. Dextran sulfate-dependent fibrinolysis in whole human plasma. J. Lab. Clin. Med. 101:1983b;214-225
140. Mori K., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J. Biochem. 89:1981;1465-1473
141. Mori K., Sakamoto W., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. III. Cleavage of HMW kininogen by the action of human salivary kallikrein. J. Biochem. 90:1981;503-509
142. Motta G., Rojkjaer R., Hasan A.A., Cines D.B., Schmaier A.H. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood. 91:1998;516-528
143. Motta G., Shariat-Madar Z., Mahdi F., Sampaio C.A., Schmaier A.H. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thromb. Haemost. 86:2001;840-847
144. Muller-Esterl W., Fritz H., Machleidt W., Ritonja A., Brzin J., Kotnik M., Turk V., Kellermann J., Lottspeich F. Human plasma kininogens are identical with α-cysteine proteinase inhibitors: Evidence from immunological, enzymological and sequence data. FEBS Lett. 182:1985a;310-314
145. Muller-Esterl W., Rauth G., Lottspeich F., Kellermann J., Henschen A. Limited proteolysis of human low-molecular-mass kininogen by tissue kallikrein: Isolation and characterization of the heavy and the light chains. Eur. J. Biochem. 149:1985b;15-22
146. Nagase H., Cawston T.E., De Silva M., Barrett A.J. Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim. Biophys. Acta. 702:1982;133-142
147. Naito K., Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII: Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J. Biol. Chem. 266:1991;7353-7358
148. Nakazawa Y., Joseph K., Kaplan A.P. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. Int. Immunopharmacol. 2:2002;1875-1885
149. Nishikawa K., Shibayama Y., Kuna P., Calcaterra E., Kaplan A.P., Reddigari S.R. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood. 80:1992;1980-1988
150. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 351:1998;1693-1697
151. Nussberger J., Cugno M., Cicardi M., Agostoni A. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104:1999;1321-1322
152. O'Donnell T.F. Jr., Clowes G.H. Jr., Talamo R.C., Colman R.W. Kinin activation in the blood of patients with sepsis. Surg. Gynecol. Obstet. 143:1976;539-545
153. Ogston D., Ogston C.M., Ratnoff O.D., Forbes C.D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: The participation of Hageman factor and additional cofactors. J. Clin. Invest. 48:1969;1786-1801
154. Ogston D., Bennett N.B., Ogston C.M., Ratnoff O.D. The assay of a plasma component necessary for the generation of a plasminogen activator in the presence of Hageman factor (Hageman factor co-factor). Br. J. Haematol. 20:1971;209-216
155. Pixley R.A., Schapira M., Colman R.W. The regulation of human factor XIIa by plasma proteinase inhibitors. J. Biol. Chem. 260:1985;1723-1729
156. Pixley R.A., Cassello A., De La Cadena R.A., Kaufman N., Colman R.W. Effect of heparin on the activation of factor XII and the contact system in plasma [see comment]. Thromb. Haemost. 66:1991;540-547
157. Pixley R.A., DeLa Cadena R.A., Page J.D., Kaufman N., Wyshock E.G., Colman R.W., Chang A., Taylor F.B. Jr. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am. J. Pathol. 140:1992;897-906
158. Pixley R.A., De La Cadena R., Page J.D., Kaufman N., Wyshock E.G., Chang A., Taylor F.B. Jr., Colman R.W. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91:1993;61-68
159. Proud D., Togias A., Naclerio R.M., Crush S.A., Norman P.S., Lichtenstein L.M. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J. Clin. Invest. 72:1983;1678-1685
160. Purdon A.D., Schapira M., De Agostini A., Colman R.W. Plasma kallikrein and prorenin in patients with hereditary angioedema. J. Lab. Clin. Med. 105:1985;694-699
161. Radcliffe R., Bagdasarian A., Colman R., Nemerson Y. Activation of bovine factor VII by hageman factor fragments. Blood. 50:1977;611-617
162. Rand M.D., Lock J.B., van't Veer C., Gaffney D.P., Mann K.G. Blood clotting in minimally altered whole blood. Blood. 88:1996;3432-3445
163. Ratnoff O.D., Naff G.B. The conversion of C′IS to C′1 esterase by plasmin and trypsin. J. Exp. Med. 125:1967;337-358
164. Reddigari S., Kaplan A.P. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood. 71:1988;1334-1340
165. Reddigari S., Kaplan A.P. Studies of the cleavage of human high molecular weight kininogen by purified plasma and tissue kallikreins, and upon contact activation of plasma. Adv. Exp. Med. Biol. 247B:1989;317-324
166. Reddigari S.R., Kuna P., Miragliotta G., Shibayama Y., Nishikawa K., Kaplan A.P. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood. 81:1993a;1306-1311
167. Reddigari S.R., Shibayama Y., Brunnee T., Kaplan A.P. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J. Biol. Chem. 268:1993b;11982-11987
168. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1980;1-46
169. Renne T., Dedio J., David G., Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 275:2000;33688-33696
170. Richter K., Muschler P., Hainzl O., Buchner J. Coordinated ATP hydrolysis by the Hsp90 dimer. J. Biol. Chem. 276:2001;33689-33696
171. Robinson J.A., Klondnycky M.L., Loeb H.S., Racic M.R., Gunnar R.M. Endotoxin, prekallikrein, complement and systemic vascular resistance: Sequential measurements in man. Am. J. Med. 59:1975;61-67
172. Rojkjaer R., Schmaier A.H. Activation of the plasma kallikrein/kinin system on endothelial cell membranes. Immunopharmacology. 43:1999a;109-114
173. Rojkjaer R., Schmaier A.H. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc. Assoc. Am. Physicians. 111:1999b;220-227
174. Rojkjaer R., Hasan A.A., Motta G., Schousboe I., Schmaier A.H. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb. Haemost. 80:1998;74-81
175. Rosing J., Tans G., Griffin J.H. Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. Eur. J. Biochem. 151:1985;531-538
176. Saito H. The participation of plasma thromboplastin antecedent (factor XI) in contact-activated fibrinolysis. Proc. Soc. Exp. Biol. Med. 164:1980;153-157
177. Saito H., Ratnoff O.D., Donaldson V.H. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ. Res. 34:1974;641-651
178. Scandura J.M., Zhang Y., Van Nostrand W.E., Walsh P.N. Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2. Biochemistry. 36:1997;412-420
179. Schapira M., Scott C.F., Colman R.W. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors: The role of high molecular weight kininogen. Biochemistry. 20:1981;2738-2743
180. Schapira M., Despland E., Scott C.F., Boxer L.A., Colman R.W. Purified human plasma kallikrein aggregates human blood neutrophils. J. Clin. Invest. 69:1982a;1199-1202
181. Schapira M., Scott C.F., James A., Silver L.D., Kueppers F., James H.L., Colman R.W. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry. 21:1982b;567-572
182. Schapira M., Scott C.F., Colman R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest. 69:1982c;462-468
183. Schapira M., Silver L.D., Scott C.F., Schmaier A.H., Prograis L.J. Jr., Curd J.G., Colman R.W. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N. Engl. J. Med. 308:1983;1050-1053
184. Schmaier A.H. Contact activation: A revision. Thromb. Haemost. 78:1997;101-107
185. Schmaier A.H. Plasma contact activation: A revised hypothesis. Biol. Res. 31:1998;251-262
186. Schmaier A.H., Kuo A., Lundberg D., Murray S., Cines D.B. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J. Biol. Chem. 263:1988;16327-16333
187. Schmaier A.H., Rojkjaer R., Shariat-Madar Z. Activation of the plasma kallikrein/kinin system on cells: A revised hypothesis. Thromb. Haemost. 82:1999;226-233
188. Schreiber A.D., Kaplan A.P., Austen K.F. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J. Clin. Invest. 52:1973;1402-1409
189. Scott C.F., Colman R.W. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J. Clin. Invest. 65:1980;413-421
190. Scott C.F., Schapira M., Colman R.W. Effect of heparin on the inactivation rate of human factor XIa by antithrombin-III. Blood. 60:1982a;940-947
191. 1-protease inhibitor and protective effect of high molecular weight kininogen. J. Clin. Invest. 69:1982b;844-852
192. Scott C.F., Silver L.D., Purdon A.D., Colman R.W. Cleavage of human high molecular weight kininogen by factor XIa in vitro: Effect on structure and function. J. Biol. Chem. 260:1985;10856-10863
193. Sealey J.E., Atlas S.A., Laragh J.H., Silverberg M., Kaplan A.P. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc. Natl. Acad. Sci. USA. 76:1979;5914-5918
194. Seligsohn U., Osterud B., Brown S.F., Griffin J.H., Rapaport S.I. Activation of human factor VII in plasma and in purified systems: Roles of activated factor IX, kallikrein, and activated factor XII. J. Clin. Invest. 64:1979;1056-1065
195. Shariat-Madar Z., Mahdi F., Schmaier A.H. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. J. Biol. Chem. 274:1999;7137-7145
196. Shariat-Madar Z., Mahdi F., Schmaier A.H. Factor XI assembly and activation on human umbilical vein endothelial cells in culture. Thromb. Haemost. 85:2001;544-551
197. Shariat-Madar Z., Mahdi F., Schmaier A.H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J. Biol. Chem. 277:2002;17962-17969
198. Sheffer A.L., Austen K.F., Rosen F.S. Tranexamic acid therapy in hereditary angioneurotic edema. N. Engl. J. Med. 287:1972;452-454
199. 9-bradykinin by angiotensin converting enzyme. Biochem. Pharmacol. 35:1986a;1951-1956
200. Sheikh I.A., Kaplan A.P. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem. Pharmacol. 35:1986b;1957-1963
201. Sheikh I.A., Kaplan A.P. The mechanism of degradation of bradykinin (lysyl-bradykinin) in human serum. Adv. Exp. Med. Biol. 247A:1989a;331-336
202. Sheikh I.A., Kaplan A.P. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum: Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem. Pharmacol. 38:1989b;993-1000
203. Shibayama Y., Joseph K., Nakazawa Y., Ghebreihiwet B., Peerschke E.I., Kaplan A.P. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated β amyloid protein. Clin. Immunol. 90:1999;89-99
204. Shoemaker L.R., Schurman S.J., Donaldson V.H., Davis A.E. III. Hereditary angioneurotic oedema: Characterization of plasma kinin and vascular permeability-enhancing activities. Clin. Exp. Immunol. 95:1994;22-28
205. r of the activating polyanion. Biochem. J. 248:1987;715-720
206. Silverberg M., Kaplan A.P. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood. 60:1982;64-70
207. Silverberg M., Dunn J.T., Garen L., Kaplan A.P. Autoactivation of human Hageman factor: Demonstration utilizing a synthetic substrate. J. Biol. Chem. 255:1980a;7281-7286
208. Silverberg M., Nicoll J.E., Kaplan A.P. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb. Res. 20:1980b;173-189
209. Silverberg M., Longo J., Kaplan A.P. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor. J. Biol. Chem. 261:1986;14965-14968
210. Sinha D., Seaman F.S., Koshy A., Knight L.C., Walsh P.N. Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. J. Clin. Invest. 73:1984;1550-1556
211. Smith D., Gilbert M., Owen W.G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 66:1985;835-839
212. Stead N., Kaplan A.P., Rosenberg R.D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J. Biol. Chem. 251:1976;6481-6488
213. Stewart J.M., Gera L., York E.J., Chan D.C., Bunn P. Bradykinin antagonists: Present progress and future prospects. Immunopharmacology. 43:1999;155-161
214. Strang C.J., Cholin S., Spragg J., Davis A.E. III, Schneeberger E.E., Donaldson V.H., Rosen F.S. Angioedema induced by a peptide derived from complement component C2. J. Exp. Med. 168:1988;1685-1698
215. Tait J.F., Fujikawa K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen: A region from residues 185 to 224 of the kininogen light chain retains full binding activity. J. Biol. Chem. 261:1986;15396-15401
216. Tait J.F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J. Biol. Chem. 262:1987;11651-11656
217. Talamo R.C., Haber E., Austen K.F. A radioimmunoassay for bradykinin in plasma and synovial fluid. J. Lab. Clin. Med. 74:1969;816-827
218. Tan Y., Hutchison F.N., Jaffa A.A. Mechanism of angiotensin II: Induced expression of B2 kinin receptors. Am. J. Physiol. Heart Circ. Physiol. 286:2004;H926-H932
219. Tankersley D.L., Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry. 23:1984;273-279
220. Tankersley D.L., Fournel M.A., Schroeder D.D. Kinetics of activation of prekallikrein by prekallikrein activator. Biochemistry. 19:1980;3121-3127
221. Thompson R.E., Mandle R. Jr., Kaplan A.P. Association of factor XI and high molecular weight kininogen in human plasma. J. Clin. Invest. 60:1977;1376-1380
222. Thompson R.E., Mandle R. Jr., Kaplan A.P. Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc. Natl. Acad. Sci. USA. 76:1979;4862-4866
223. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:1983;655-709
224. Tuszynski G.P., Bevacqua S.J., Schmaier A.H., Colman R.W., Walsh P.N. Factor XI antigen and activity in human platelets. Blood. 59:1982;1148-1156
225. van der Graaf F., Koedam J.A., Bouma B.N. Inactivation of kallikrein in human plasma. J. Clin. Invest. 71:1983a;149-158
226. van der Graaf F., Koedam J.A., Griffin J.H., Bouma B.N. Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry. 22:1983b;4860-4866
227. van Iwaarden F., de Groot P.G., Bouma B.N. The binding of high molecular weight kininogen to cultured human endothelial cells. J. Biol. Chem. 263:1988;4698-4703
228. Vavrek R.J., Stewart J.M. Competitive antagonists of bradykinin. Peptides. 6:1985;161-164
229. Vennerod A.M., Laake K., Solberg A.K., Stromland S. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thromb. Res. 9:1976;457-466
230. von dem Borne P.A., Koppelman S.J., Bouma B.N., Meijers J.C. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb. Haemost. 72:1994;397-402
231. Wachtfogel Y.T., Pixley R.A., Kucich U., Abrams W., Weinbaum G., Schapira M., Colman R.W. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood. 67:1986;1731-1737
232. Wachtfogel Y.T., DeLa Cadena R.A., Kunapuli S.P., Rick L., Miller M., Schultze R.L., Altieri D.C., Edgington T.S., Colman R.W. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J. Biol. Chem. 269:1994;19307-19312
233. Wallace E.M., Perkins S.J., Sim R.B., Willis A.C., Feighery C., Jackson J. Degradation of C1-inhibitor by plasmin: Implications for the control of inflammatory processes. Mol. Med. 3:1997;385-396
234. Walsh P.N., Griffin J.H. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood. 57:1981;106-118
235. Weiss A.S., Gallin J.I., Kaplan A.P. Fletcher factor deficiency: A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. Clin. Invest. 53:1974;622-633
236. Wiggins R.C., Bouma B.N., Cochrane C.G., Griffin J.H. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc. Natl. Acad. Sci. USA. 74:1977;4636-4640
237. Wuepper K.D. Prekallikrein deficiency in man. J. Exp. Med. 138:1973;1345-1355
238. Wuepper K.D., Miller D.R., Lacombe M.J. Flaujeac trait: Deficiency of human plasma kininogen. J. Clin. Invest. 56:1975;1663-1672
239. Wuillemin W.A., Minnema M., Meijers J.C., Roem D., Eerenberg A.J., Nuijens J.H., ten Cate H., Hack C.E. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: Major role for C1-inhibitor. Blood. 85:1995;1517-1526
240. Wuillemin W.A., Eldering E., Citarella F., de Ruig C.P., ten Cate H., Hack C.E. Modulation of contact system proteases by glycosaminoglycans: Selective enhancement of the inhibition of factor XIa. J. Biol. Chem. 271:1996;12913-12918
241. Yang H.Y., Erdos E.G. Second kininase in human blood plasma. Nature. 215:1967;1402-1403
242. Yokosawa N., Takahashi N., Inagami T., Page D.L. Isolation of completely inactive plasma prorenin and its activation by kallikreins: A possible new link between renin and kallikrein. Biochim. Biophys. Acta. 569:1979;211-219
243. Zahedi R., Bissler J.J., Davis A.E. III, Andreadis C., Wisnieski J.J. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443 → Val substitution and functional analysis of the recombinant mutant protein. J. Clin. Invest. 95:1995;1299-1305
244. Zahedi R., Wisnieski J., Davis A.E. III. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: Inhibition of complement and contact system proteases. J. Immunol. 159:1997;983-988
245. Zhang Y., Scandura J.M., Van Nostrand W.E., Walsh P.N. The mechanism by which heparin promotes the inhibition of coagulation factor XIa by protease nexin-2. J. Biol. Chem. 272:1997;26139-26144
246. Zhao Y., Qiu Q., Mahdi F., Shariat-Madar Z., Rojkjaer R., Schmaier A.H. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am. J. Physiol. Heart Circ. Physiol. 280:2001;H1821-H1829